Taste alterations during neo/adjuvant chemotherapy and subsequent follow-up in breast cancer patients: a prospective single-center clinical study

Purpose Dysgeusia and taste alterations (TAs) are side effects of cytotoxic chemotherapy and affect patients’ quality of life; however, the prevalence, types, and duration of TAs and their potential relationship with other clinical disturbances are not well-described. Our primary aim was to prospect...

Full description

Saved in:
Bibliographic Details
Published in:Supportive care in cancer 2022-08, Vol.30 (8), p.6955-6961
Main Authors: Pedersini, Rebecca, Zamparini, Manuel, Bosio, Sara, di Mauro, Pierluigi, Turla, Antonella, Monteverdi, Sara, Zanini, Alessandra, Amoroso, Vito, Vassalli, Lucia, Cosentini, Deborah, Grisanti, Salvatore, Simoncini, Edda Lucia, Berruti, Alfredo
Format: Article
Language:English
Subjects:
Adjuvant treatment
Anthracyclines
Breast cancer
Cancer
Cancer patients
Care and treatment
Chemosensory perception
Chemotherapy
Clinical trials
Medicine
Medicine & Public Health
Nausea
Nursing
Nursing Research
Oncology
Oncology, Experimental
Original Article
Pain Medicine
Rehabilitation Medicine
Side effects
Taste
Taste disorders
Terminology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Dysgeusia and taste alterations (TAs) are side effects of cytotoxic chemotherapy and affect patients’ quality of life; however, the prevalence, types, and duration of TAs and their potential relationship with other clinical disturbances are not well-described. Our primary aim was to prospectively evaluate the characteristics of TAs in early breast cancer (EBC) patients during (neo)adjuvant chemotherapy and up to 1 year after its completion. Methods From April 2014 to June 2018, 182 EBC patients entered the study and received (neo)adjuvant chemotherapy, mostly with taxane and anthracycline-containing regimens (65% of cases). A dietitian performed TAs assessment through the Common Terminology Criteria for Adverse Event v4.0 (CTCAE) and the Chemotherapy-induced Taste Alteration Scale (CiTAS) questionnaire during chemotherapy and follow-up according to defined time points: at baseline (T0, before starting chemotherapy); at the first follow-up visit, (T1, 2 months after starting chemotherapy); at the final follow-up visit (T2, 1 week after completing chemotherapy); after that, every 3 months up to 12 months. Results Dysgeusia was reported by 69.8% of patients at T1 and declined subsequently; salty flavor distortion was the most frequently reported TA (51.6% of cases). CiTAS was significantly different between T0 and T2 ( p  
ISSN:0941-4355
1433-7339
DOI:10.1007/s00520-022-07091-6